Correlation Between GDF11 Serum Levels, Severity of Coronary Artery Lesions, and the Prognosis of Patients with ST-segment Elevation Myocardial Infarction

J Cardiovasc Transl Res. 2023 Aug;16(4):938-947. doi: 10.1007/s12265-023-10358-w. Epub 2023 Feb 7.

Abstract

We aimed to explore the correlation among serum GDF11, the severity of coronary artery lesions, and the prognosis of patients with ST-segment elevation myocardial infarction (STEMI). A total of 367 patients were enrolled and divided into control (n = 172) and STEMI (n = 195) groups. Serum GDF11 (P < 0.001) was an independent predictor of STEMI and was negatively correlated with SYNTAX score (P < 0.05). ROC curve analysis showed that serum GDF11 could screen patients for major adverse cardiovascular events (MACEs). KM curve analysis showed that patients with lower concentration of GDF11 had a higher incidence of MACEs, and Cox proportional hazards regression analysis showed that the serum GDF11 (P < 0.001) was an independent predictor of MACEs. Serum GDF11 was negatively correlated with the severity of coronary lesions and was also an independent prognostic indicator of MACEs in patients with STEMI.

Keywords: Growth differentiation factor 11; Major adverse cardiovascular events.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bone Morphogenetic Proteins
  • Coronary Vessels / pathology
  • Growth Differentiation Factors
  • Heart
  • Humans
  • Percutaneous Coronary Intervention* / adverse effects
  • Prognosis
  • ST Elevation Myocardial Infarction* / diagnostic imaging
  • ST Elevation Myocardial Infarction* / therapy

Substances

  • GDF11 protein, human
  • Bone Morphogenetic Proteins
  • Growth Differentiation Factors